NATtrol SARS-Related Coronavirus 2 (SARS-CoV-2) Stock |
NATSARS(COV2)-ST |
Zeptometrix |
Stock |
EUR 935 |
Human IgG antibody Laboratories manufactures the § nattrol treated sars-cov molecular controls reagents distributed by Genprice. The § Nattrol Treated Sars-Cov Molecular Controls reagent is RUO (Research Use Only) to test human serum or cell culture lab samples. To purchase these products, for the MSDS, Data Sheet, protocol, storage conditions/temperature or for the concentration, please contact SARS NATtrol. Other § products are available in stock. Specificity: § Category: Nattrol Group: Treated Sars-Cov
SARS-CoV Matrix Antibody |
ProSci |
0.1 mg |
EUR 523.7 |
|
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. The membrane (M) protein or matrix protein is the most abundant structural protein and defines the shape of the viral envelope (3). It is an integral membrane protein involved in the budding of the viral particles and interacts with S (Spike) protein. It involves in organization of the nucleoprotein inside, which includes many copies of the N (nucleocapsid) protein bound to the genomic RNA. The M protein holds dominant cellular immunogenicity and has been determined as a protective antigen in humoral responses, which suggests it would serve as a potential target in vaccine design (4). |
SARS-CoV Matrix Antibody |
ProSci |
0.02 mg |
EUR 206.18 |
|
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus. The disease is the cause of the 2019–20 coronavirus outbreak (1). SARS-CoV-2 is the seventh member of the enveloped, positive-stranded RNA viruses that are able to infect humans. The SARS-CoV-2 genome, like other coronaviruses, encodes for multiple structural and nonstructural proteins. The structural proteins include spike protein (S), envelope protein (E), membrane glycoprotein (M), nucleocapsid phosphoprotein (N), and the nonstructural proteins include open reading frame 1ab (ORF1ab), ORF3a, ORF6, ORF7a, ORF8, and ORF10 (2).The membrane (M) protein or matrix protein is the most abundant structural protein and defines the shape of the viral envelope (3). It is an integral membrane protein involved in the budding of the viral particles and interacts with S (Spike) protein. It involves in organization of the nucleoprotein inside, which includes many copies of the N (nucleocapsid) protein bound to the genomic RNA. The M protein holds dominant cellular immunogenicity and has been determined as a protective antigen in humoral responses, which suggests it would serve as a potential target in vaccine design (4). |
SARS-CoV Matrix Antibody |
ProSci |
0.1 mg |
EUR 523.7 |
|
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus. The disease is the cause of the 2019–20 coronavirus outbreak (1). SARS-CoV-2 is the seventh member of the enveloped, positive-stranded RNA viruses that are able to infect humans. The SARS-CoV-2 genome, like other coronaviruses, encodes for multiple structural and nonstructural proteins. The structural proteins include spike protein (S), envelope protein (E), membrane glycoprotein (M), nucleocapsid phosphoprotein (N), and the nonstructural proteins include open reading frame 1ab (ORF1ab), ORF3a, ORF6, ORF7a, ORF8, and ORF10 (2).The membrane (M) protein or matrix protein is the most abundant structural protein and defines the shape of the viral envelope (3). It is an integral membrane protein involved in the budding of the viral particles and interacts with S (Spike) protein. It involves in organization of the nucleoprotein inside, which includes many copies of the N (nucleocapsid) protein bound to the genomic RNA. The M protein holds dominant cellular immunogenicity and has been determined as a protective antigen in humoral responses, which suggests it would serve as a potential target in vaccine design (4). |
SARS-CoV Envelope Antibody |
ProSci |
0.02 mg |
EUR 206.18 |
|
Description: SARS Envelope Antibody: A novel coronavirus has recently been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2.Envelope protein is a small polypeptide that contains at least one α-helical transmembrane domain. It involves in several aspects of the virus's life cycle, such as assembly, budding, envelope formation, and pathogenesis. E protein has membrane permeabilizing activity, which provides a possible rationale to inhibit in vitro ion channel activity of some synthetic coronavirus E proteins, and also viral replication. |
SARS-CoV Envelope Antibody |
ProSci |
0.1 mg |
EUR 523.7 |
|
Description: SARS Envelope Antibody: A novel coronavirus has recently been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2.Envelope protein is a small polypeptide that contains at least one α-helical transmembrane domain. It involves in several aspects of the virus's life cycle, such as assembly, budding, envelope formation, and pathogenesis. E protein has membrane permeabilizing activity, which provides a possible rationale to inhibit in vitro ion channel activity of some synthetic coronavirus E proteins, and also viral replication. |
SARS-CoV Spike Antibody |
ProSci |
0.02 mg |
EUR 206.18 |
|
Description: SARS-CoV Spike Antibody: A novel coronavirus has been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2. |
SARS-CoV Spike Antibody |
ProSci |
0.1 mg |
EUR 523.7 |
|
Description: SARS-CoV Spike Antibody: A novel coronavirus has been identified as the causative agent of SARS (Severe Acute Respiratory Syndrome). Coronaviruses are a major cause of upper respiratory diseases in humans. The genomes of these viruses are positive-stranded RNA approximately 27-31kb in length. SARS infection can be mediated by the binding of the viral spike protein, a glycosylated 139 kDa protein and the major surface antigen of the virus, to the angiotensin-converting enzyme 2 (ACE2) on target cells. This binding can be blocked by a soluble form of ACE2. |
Treated Sars-Cov information
NATtrol RSV Positive Control (6 x 0.5mL) |
NATRSV-6C |
Zeptometrix |
6 x 0.5mL |
EUR 222 |
NATtrol BV Negative Control (6 X 0.15mL) |
NATBVNEG-BD |
Zeptometrix |
6 X 0.15mL |
EUR 295 |
NATtrol BV Positive Control (6 X 0.15mL) |
NATBVPOS-BD |
Zeptometrix |
6 X 0.15mL |
EUR 446 |
NATtrol Candida/TV Positive Control (ea) |
NATCTVPOS-BD |
Zeptometrix |
ea |
EUR 446 |
NATtrol EV Negative Control (6 X 0.2 mL) |
NATEVNEG-6MC |
Zeptometrix |
6 X 0.2 mL |
EUR 208 |
NATtrol EV Positive Control (6 X 0.2 mL) |
NATEVPOS-6MC |
Zeptometrix |
6 X 0.2 mL |
EUR 208 |
NATtrol SA Positive Control (6 X 0.5 mL) |
NATMSSA-6MC |
Zeptometrix |
6 X 0.5 mL |
EUR 311 |
NATtrol SA Positive Control (6 X 0.5 mL) |
NATMSSA-6MC-IVD |
Zeptometrix |
6 X 0.5 mL |
EUR 331 |
NATtrol EV Positive Control (6 X 0.5 mL) |
MDZ055 |
Zeptometrix |
6 X 0.2 mL |
EUR 208 |
NATtrol EV Negative Control (6 X 0.5 mL) |
MDZ056 |
Zeptometrix |
6 X 0.2 mL |
EUR 208 |
NATtrol SA Positive Control (6 X 0.5 mL) |
MDZ061 |
Zeptometrix |
6 X 0.5 mL |
EUR 378.24 |
|
Description: Please contact Gentaur in order to receive the datasheet of the product. |
NATtrol Parainfluenza Control (6 X 0.5mL) |
NATPIV-ERC |
Zeptometrix |
6 X 0.5mL |
EUR 265 |
NATtrol GBS Negative Control (6 X 0.5 mL) |
NATLAC-6MC |
Zeptometrix |
6 X 0.5 mL |
EUR 313 |
NATtrol GBS Negative Control (6 X 0.5 mL) |
NATLAC-6MC-IVD |
Zeptometrix |
6 X 0.5 mL |
EUR 333 |
NATtrol RSV Positive Control (6 X 0.5 mL) |
NATRSV-6C-IVD |
Zeptometrix |
6 X 0.5 mL |
EUR 242 |
NATtrol GBS Positive Control (6 x 0.25 mL) |
NATSAG-6L |
Zeptometrix |
6 x 0.25 mL |
EUR 272 |
NATtrol GBS Positive Control (6 X 0.5 mL) |
NATSAG-6MC |
Zeptometrix |
6 X 0.5 mL |
EUR 313 |